Issue Archive

Edited by Associate Editor John Crispino, this Review Series focuses on hematopoietic stem cell (HSC) biology, going beyond the work in murine HSC biology and emphasizing development and characterization of human HSCs. Expert authors in the field cover topics ranging from ontogeny to aging and leukemia transformation. We hope that these erudite articles will stimulate research that develops novel strategies to reverse the effects of aging, prevent malignant transformation, and enhance in vitro production of HSCs from pluripotent stem cells.

Edited by Associate Editor John Crispino, this Review Series focuses on hematopoietic stem cell (HSC) biology, going beyond the work in murine HSC biology and emphasizing development and characterization of human HSCs. Expert authors in the field cover topics ranging from ontogeny to aging and leukemia transformation. We hope that these erudite articles will stimulate research that develops novel strategies to reverse the effects of aging, prevent malignant transformation, and enhance in vitro production of HSCs from pluripotent stem cells.

Edited by Associate Editor John Crispino, this Review Series focuses on hematopoietic stem cell (HSC) biology, going beyond the work in murine HSC biology and emphasizing development and characterization of human HSCs. Expert authors in the field cover topics ranging from ontogeny to aging and leukemia transformation. We hope that these erudite articles will stimulate research that develops novel strategies to reverse the effects of aging, prevent malignant transformation, and enhance in vitro production of HSCs from pluripotent stem cells.

Edited by Associate Editor John Crispino, this Review Series focuses on hematopoietic stem cell (HSC) biology, going beyond the work in murine HSC biology and emphasizing development and characterization of human HSCs. Expert authors in the field cover topics ranging from ontogeny to aging and leukemia transformation. We hope that these erudite articles will stimulate research that develops novel strategies to reverse the effects of aging, prevent malignant transformation, and enhance in vitro production of HSCs from pluripotent stem cells.

Edited by Associate Editor John Crispino, this Review Series focuses on hematopoietic stem cell (HSC) biology, going beyond the work in murine HSC biology and emphasizing development and characterization of human HSCs. Expert authors in the field cover topics ranging from ontogeny to aging and leukemia transformation. We hope that these erudite articles will stimulate research that develops novel strategies to reverse the effects of aging, prevent malignant transformation, and enhance in vitro production of HSCs from pluripotent stem cells.

Now recognized as an indolent B-cell lymphoma, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) poses a conundrum for patients and treating physicians: should treatment follow traditional Hodgkin lymphoma (HL) paradigms or those for management of lymphomas of similar cells of origin? Although they don’t answer this question, Eichenauer and colleagues provide compelling data from 2 prospective trials indicating outstanding patient outcomes with HL regimens for early stage NLPHL, with >90% 5-year progression-free and 100% overall survival. Importantly, the authors identify that consolidation radiotherapy appears necessary to achieve optimal disease control irrespective of interim positron emission tomography (PET) results.

Follicular lymphoma (FL) shares many genetic events with the germinal center–subtype of diffuse large B-cell lymphoma (DLBCL), and transformation to aggressive lymphoma is a preterminal event for many patients with FL. Dreval et al used whole genome sequencing, comparing FL cases with and without histological transformation, to elucidate transformation to DLBCL. The authors discovered 2 genetically distinct subgroups of FL: DLCBL-like FL (dFL) and constrained FL (cFL) that show a 10-year difference in time to transformation. cFL/dFL designation is an independent classifier that identifies high-risk patients, providing a new paradigm for mechanisms and risk for transformation.

Qiu and colleagues shed light on the metabolic changes that arise in a population of chronic myelogenous leukemia (CML) stem cells that allow them to better adapt to continued tyrosine kinase inhibitor (TKI) treatment. Exploiting a murine model and patient-derived xenografts, the authors show that hypoxia-inducible factor 1 (HIF-1) activation plays a critical role in this adaptation to TKI treatment by restricting oxidative phosphorylation and maintaining stem cell dormancy. Adding HIF-1 inhibition to TKI therapy is posited as a novel way to deplete persistent, quiescent CML stem cells.

During severe infections, neutrophils are rapidly consumed, and production is urgently accelerated. Resolution of acute inflammation is thought to be an active process governed by the production of endogenous specialized proresolving lipid mediators, including the resolvin family. Using murine models of bacterial infection and single-cell mass cytometry, Libreros et al report that an increase in resolvin D4 disengages emergency granulopoiesis and limits excessive neutrophil accumulation at the inflamed site, promoting return to homeostasis following infection.

Genetic variants identified in complement factor I (CFI) are pathogenic in ∼15% of patients with atypical hemolytic uremic syndrome. Using mutagenesis studies, Java and colleagues demonstrate that mutations at these sites that surround the calcium-binding sites cause defective protein synthesis with minimal or no secretion, suggesting that calcium is critical for CFI structure and function.